ABSTRACT
INTRODUCTION
Malignant pleural effusion (MPE) is one of the leading causes of pleural effusions and a common cause of morbidity worldwide [1] . MPE can complicate most cancers, including extra-pleural malignancies, especially lung and breast carcinomas, as well as primary pleural mesothelioma.
The pathophysiology of MPE remains unclear but is believed to involve increased plasma extravasation from hyper-permeable tumor and/or pleural MPE fluid bathes the pleural tumors and is a rich source of their secretory products including growth factors, eg vascular endothelial growth factor (VEGF), as well as cytokines/chemokines that promote tumor proliferation, eg interleukin (IL)-6 [2] , IL-8 [3] , and monocyte chemoattractant protein-1 (MCP-1) [4] etc. These molecules are present in significantly higher concentrations in the MPE than in corresponding sera, implying their local pleural synthesis. These proteins have potent biological effects and are involved in complex interplay between the host and tumor cells to execute pro-inflammatory and pro-angiogenic transcriptional programs that induce pleural inflammation, vascular hyper-permeability and tumor angiogenesis [5] . Charting the changes of these molecules during disease progression may provide clues to pleural tumor pathobiology, and may explore their potential as biomarkers of patient survival or disease activity.
A major limitation in pleural research to date is that bio-specimens available for investigations, eg pleural fluid for biochemical and immunological profiling, are restricted to single cross-sectional samples. Repeated sampling (eg biopsies or thoracentesis) is not practical or ethical. Heterogeneity from inter-individual differences (eg genetics, cancer stages) poses major hurdles to researchers. The pleural milieu will almost certainly change throughout the disease course, and be influenced by the type, stage, progression (and treatment response) of the underlying cancer as well as host comorbidity etc.
Existing literature on the longitudinal changes in malignant pleural fluid analyses is limited to one pilot study (n=9). IPC is now an established treatment for MPE [6, 7] , and has been shown to provide comparable symptomatic benefits as talc pleurodesis with shorter hospitalization. The advent of IPC offers a unique opportunity, not possible before, to provide serial pleural fluid during the patients' disease course and an exciting opportunity to longitudinally study pleural cancer biology within and between individuals.
This study aimed to describe the longitudinal changes in pleural fluid biochemistry and levels of key cytokines/chemokines in patients with an MPE. 
METHODS

During
Biochemistry and hematology measurement methods
Protein, albumin, LDH, glucose and CRP levels in blood and/or pleural fluid were measured by spectrophotometry using an Abbott Architect c16000 analyzer (Abbott Park, Illinois, USA). Pleural fluid pH was measured using a Radiometer ABL 800 blood-gas analyzer (Åkandevej, Brønshøj, Denmark). Hemoglobin, total white blood cells, neutrophils, lymphocytes, and platelets were quantified with the Beckman Coulter DxH800 analyzer (Brea, CA, USA), following standard manufacturer's instructions. All the measurements were performed at our hospital National Association of Testing Authorities-accredited laboratory.
Cytokine measurement method
Enzyme-linked immunosorbent assays (ELISAs) were used to measure concentrations of VEGF, IL-6 and IL-8 (R&D, Minneapolis, MN), and MCP-1, IL-10, INFγ and TNF-α (eBiosciences, San Diego, CA, USA).
Serial samples of each patient were assayed in duplicate in the same ELISA run. The colorimetric assay was quantified by a spectrophotometer and adjusted for background.
Statistical analyses
Longitudinal changes in pleural fluid biochemistry and cytokines, serum biochemistry, and blood counts were analyzed using linear mixed models; specifically, a straight-line model with varying intercepts and varying slopes for each individual was employed. The response at the population level was modeled, either on the original scale or on a log scale, via mixed-effects linear regression using "time since first pleural fluid collection" as sole regressor. The intercepts and slopes of individuals were assumed to vary randomly about these population parameters, with this variation modeled by a bivariate normal distribution. Results reported are for the population parameters of this model.
Mathematical details:
In mathematical notation the models fitted are as follows: Let y ij be the response variable measured on individual i at time point
Here n is the total number of individuals and n i the number of measurements taken on individual i, with the j th observation y ij taken at time
The following linear mixed model was fitted to these data:
where β 0 and β 1 denote the population intercept and slope, respectively.
The random effects b 0i and b 1i allow the intercept and slope of the line fitted to individual i to vary about the population parameters. The joint distribution of these random effects is modeled as being a bivariate normal distribution with mean vector zero and a general variance covariance matrix.
The error term, ε ij , is assumed to be normally distributed, and independent of the random effects. The protein concentrations in the pleural fluid decreased over time while its levels remained stable in the serum. It is noteworthy that repeated removal of exudative malignant fluid via IPC drainage did not result in noticeable reduction in systemic protein levels, a concern that has been raised regarding IPC use. Pleural fluid protein is generally regarded as a marker of plasma leakage from vascular hyper-permeability in the pleura [5] . Pleural fluid protein level in the exudative range can be found in more than 60 diseases, and is a key mechanism underlying malignant effusion formation.
Plasma leakage in MPE is believed to be driven by mechanisms induced by local pleural tumor and substances released by it. No data exist on longitudinal measurements of effusion protein but it would be expected to rise with progression of pleural malignancy; our data showed otherwise. We hypothesize that reduction in pleural fluid protein level results from concurrent driving forces of formation of low protein pleural fluid, such as heart failure, presence of trapped lung, and low systemic protein levels from cancer-associated malnutrition. Our data suggests that the final pleural fluid protein levels would likely not have fulfilled the exudate criteria; however, the fluid would fulfill Light's criteria for exudate as the LDH levels remained high.
Our data showed that serum albumin, but not protein, level decline longitudinally in this cohort. 
